氨溴索雾化吸入联合人免疫球蛋白静脉滴注治疗重症肺炎患儿的临床疗效  

Clinical Efficacy of Ambroxol Inhalation Combined with Intravenous Drip of Human Immunoglobulin in the Treatment of Children with Severe Pneumonia

作　　者：王芳 WANG Fang(Department of Pediatric critical Care Unit,Wuwei Liangzhou Hospital,Wuwei 733000,China)

机构地区：[1]甘肃省武威市凉州医院小儿重症医学科,甘肃武威733000

出　　处：《中国医药指南》2020年第22期62-63,共2页Guide of China Medicine

摘　　要：目的分析氨溴索雾化吸入联合人免疫球蛋白静脉滴注治疗重症肺炎患儿的临床疗效。方法回顾性分析2017年12月至2019年12月甘肃省武威市凉州医院收治的100例重症肺炎患儿的临床资料,依据不同的治疗方法将患儿分为对照组和观察组,各50例。对照组患儿采用氨溴索进行雾化吸入治疗,观察组患儿在对照组基础上联用人免疫球蛋白静脉滴注治疗,将两组患儿的临床治疗效果进行比较。结果观察组治疗有效率高于对照组,组间具有显著差异(P<0.05);观察组患儿体温恢复时间、肺啰音消失时间及住院时间均短于对照组,组间具有显著差异(均P<0.05);治疗后,两组患儿用力肺活量、第1秒呼吸容积、呼吸峰流速、最大呼气压及最大吸气压均优于治疗前,且观察组改善情况比对照组更为显著,差异均有统计学意义(均P<0.05);观察组患儿不良反应发生率低于对照组,组间具有显著差异(P<0.05)。结论氨溴索雾化吸入联合人免疫球蛋白静脉滴注治疗重症肺炎患儿有利于提升治疗效果,改善患儿肺功能指标及临床症状。Objective To analyze the clinical efficacy of ambroxol inhalation combined with intravenous drip of human immunoglobulin in the treatment of children with severe pneumonia.Methods The clinical data of 100 children with severe pneumonia admitted to Liangzhou Hospital of Wuwei City from December 2017 to December 2019 were retrospectively analyzed.They were divided into the control group and the observation group according to different treatment methods,50 cases in each group.The control group was treated with ambroxol inhalation,the observation group was treated with intravenous drip of human immunoglobulin on the basis of the control group.The clinical efficacy of the two groups were compared.Results The effective rate of the observation group was higher than that of the control group,there are significant differences between two groups(P<0.05).The recovery time of body temperature,disappearance time of pulmonary rales and hospitalization time in the observation group were shorter than those in the control group,there are significant differences between two groups(P<0.05).After treatment,the forced vital capacity,first respiratory volume,respiratory peak flow rate,maximum expiratory pressure and maximum inspiratory pressure lung function indexes of the two groups were better than those before treatment,and the improvement of the observation group was more significant than that of the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was lower than that in the control group,there are significant differences between two groups(P<0.05).Conclusion In the treatment of children with severe pneumonia,ambroxol inhalation combined with intravenous drip of human immunoglobulin is conducive to the promotion and optimization of the treatment effect of children with severe pneumonia,which has positive value for improving the health of children,lung function indicators and clinical symptoms.

关 键 词：重症肺炎 儿童 氨溴索 人免疫球蛋白 肺功能 

分 类 号：R563.1[医药卫生—呼吸系统] R725.6[医药卫生—内科学]